The goal of this clinical trial is to (PART 1) to measure the whether it is safe and how hard side effects are to live with of a single subcutaneous injection of HB0017 Injection in healthy subjects with low body weight; ( PART 2) to compare the pharmacokinetics (PK) of HB0017 following single subcutaneous administration at different injection sites at the same dose.
Official registry: https://clinicaltrials.gov/study/NCT07920861 · Huabo Biopharm Co., Ltd. · enrollment listed as 90
Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are HB0017 Injection, or HB0017 Placebo. The registry lists allocation as randomized. The goal of this clinical trial is to (PART 1) to measure the whether it is safe and how hard side effects are to live with of a single subcutaneous injection of HB0017 Injection in healthy subjects with low body weight; ( PART 2) to compare the pharmacokinetics (PK) of HB0017 following single subcutaneous administration at different injection sites at the same dose.
They plan to enroll about 90 people at Hangzhou. Taking part typically means an infusion or injection of a biologic plus check-ins.
A Study of HB0017 Injection to Investigate PK After Subcutaneous Administration at Different Injection Sites in Healthy Volunteers, and to Evaluate Its Safety, Tolerability, and Pharmacokinetics in Low-body-weight Healthy Subjects
Interventions: HB0017 Injection, HB0017 Placebo
Primary outcome (registry wording): Adverse events
Ying Wang, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.
NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit
The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.
NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary